Related Experiment Videos
A controlled double-blind study comparing binedaline and imipramine in the treatment of endogenous depression
Insights
Binedaline and imipramine showed equal effectiveness in treating depression. Binedaline, however, resulted in fewer side effects, particularly anticholinergic ones, making it a potentially preferable treatment option.
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Major depressive disorder is a significant global health concern.
- Imipramine is a well-established tricyclic antidepressant.
- Binedaline is a novel antidepressant agent.
Purpose of the Study:
- To compare the efficacy and safety of binedaline versus imipramine in hospitalized patients with endogenous depression.
- To evaluate treatment outcomes using standardized depression rating scales and clinical global impression.
Main Methods:
- A randomized controlled trial involving 50 hospitalized patients with endogenous depression (Hamilton Depression Rating Scale score >= 18).
- Patients received either imipramine (150 mg/day) or binedaline (300 mg/day) for 30 days.
- Clinical and laboratory assessments, including Hamilton and Zung depression scores, were conducted at baseline and on days 1, 3, 5, 15, and 30.
Main Results:
- Both imipramine and binedaline significantly reduced Hamilton and Zung depression scores by day 30 compared to baseline.
- No statistically significant differences in psychiatric or clinical efficacy were observed between the two treatment groups.
- The Clinical Global Impression scale showed slightly higher efficacy in the binedaline group.
- The frequency of side effects, especially anticholinergic effects, was significantly lower in the binedaline group.
Conclusions:
- Binedaline demonstrates comparable antidepressant efficacy to imipramine.
- Binedaline offers an improved side effect profile, with a notable reduction in anticholinergic adverse events.
- Binedaline represents a potentially safer alternative for the treatment of major depressive disorder.
Unlabelled:
50 hospitalized endogenously depressed patients (age 20-60 years, HAM-D greater than or equal to 18) were treated daily with 3 X 50 mg imipramine or 3 X 100 mg binedaline. Clinical and laboratory assessments were done before and on days 1, 3, 5, 15 and 30 of treatment. Mean Hamilton and Zung scores were statistically significant lower on day 30 when compared with pretreatment scores. No psychiatric, clinical or statistical differences were noted between the two groups. The efficacy of the clinical global impression scale was slightly higher in the binedaline groups. Frequency of side effects (specially anticholinergic) was lower in the binedaline group.
Conclusion:
binedaline is equally effective as imipramine, but with less side effects.